Glaukos Corporation Company Profile (NYSE:GKOS)

About Glaukos Corporation

Glaukos Corporation logoGlaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a corneal incision. The Company's micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: GKOS
  • CUSIP:
Key Metrics:
  • Previous Close: $45.50
  • 50 Day Moving Average: $42.22
  • 200 Day Moving Average: $36.13
  • 52-Week Range: $15.00 - $47.50
  • Trailing P/E Ratio: 812.46
  • Foreward P/E Ratio: 197.83
  • P/E Growth: 15.43
  • Market Cap: $1.55B
  • Outstanding Shares: 33,549,000
  • Beta: 1.37
  • Net Margins: 2.07%
  • Return on Equity: 2.05%
  • Return on Assets: 1.73%
  • Current Ratio: 6.08%
  • Quick Ratio: 5.74%
Additional Links:
Companies Related to Glaukos Corporation:

Analyst Ratings

Consensus Ratings for Glaukos Corporation (NYSE:GKOS) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $44.17 (2.93% downside)

Analysts' Ratings History for Glaukos Corporation (NYSE:GKOS)
DateFirmActionRatingPrice TargetDetails
2/28/2017Stifel NicolausBoost Price TargetPositive$45.00 -> $55.00View Rating Details
2/22/2017BMO Capital MarketsInitiated CoverageOutperform$54.00View Rating Details
11/30/2016Cantor FitzgeraldReiterated RatingBuy$41.00 -> $45.00View Rating Details
10/27/2016Wells Fargo & CoInitiated CoverageOutperformView Rating Details
8/2/2016Roth CapitalBoost Price TargetBuy$36.50 -> $41.00View Rating Details
8/2/2016Piper Jaffray CompaniesBoost Price Target$42.00View Rating Details
3/2/2016J P Morgan Chase & CoLower Price TargetOverweight$32.00 -> $28.00View Rating Details
11/19/2015William BlairReiterated RatingOutperformView Rating Details
8/27/2015Goldman Sachs Group IncLower Price Target$33.00 -> $32.00View Rating Details
7/20/2015Bank of America CorpInitiated CoverageBuy$37.00View Rating Details
7/20/2015Canaccord GenuityInitiated CoverageBuy$35.00View Rating Details
(Data available from 3/1/2015 forward)


Earnings History for Glaukos Corporation (NYSE:GKOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q416$0.00$29.49 millionN/AView Earnings Details
11/10/2016Q316$0.00$0.03$27.21 million$29.60 millionViewN/AView Earnings Details
8/1/2016Q216($0.04)$0.06$24.45 million$28.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.15)$0.03$18.77 million$23.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.13)($0.07)$20.07 million$20.28 millionViewN/AView Earnings Details
11/10/2015Q315($0.17)($0.07)$17.93 million$19.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Glaukos Corporation (NYSE:GKOS)
Current Year EPS Consensus Estimate: $0.12 EPS
Next Year EPS Consensus Estimate: $0.23 EPS


Dividend History for Glaukos Corporation (NYSE:GKOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Glaukos Corporation (NYSE:GKOS)
Insider Ownership Percentage: 36.80%
Institutional Ownership Percentage: 77.95%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/2/2017Thomas William BurnsCEOSell50,000$42.58$2,129,000.00View SEC Filing  
1/13/2017Chris M CalcaterraInsiderSell18,136$40.01$725,621.36View SEC Filing  
1/13/2017Richard L HarrisonCFOSell20,634$40.00$825,360.00View SEC Filing  
1/9/2017Chris M CalcaterraInsiderSell20,000$38.02$760,400.00View SEC Filing  
1/9/2017Thomas William BurnsCEOSell40,000$37.60$1,504,000.00View SEC Filing  
1/6/2017Richard L HarrisonCFOSell20,634$35.58$734,157.72View SEC Filing  
11/17/2016William J Phd LinkDirectorSell30,000$33.78$1,013,400.00View SEC Filing  
11/15/2016Thomas William BurnsCEOSell200,120$33.68$6,740,041.60View SEC Filing  
10/24/2016Chris M CalcaterraInsiderSell20,000$36.01$720,200.00View SEC Filing  
10/20/2016Chris M CalcaterraInsiderSell40,000$34.76$1,390,400.00View SEC Filing  
8/12/2016Jonathan SilversteinDirectorSell292,938$33.69$9,869,081.22View SEC Filing  
8/3/2016Orbimed Advisors LlcDirectorSell425,000$30.59$13,000,750.00View SEC Filing  
7/27/2016Richard L HarrisonCFOSell10,000$35.01$350,100.00View SEC Filing  
7/13/2016Thomas William BurnsCEOSell162,254$30.07$4,878,977.78View SEC Filing  
7/12/2016Richard L HarrisonCFOSell5,700$30.00$171,000.00View SEC Filing  
6/20/2016Richard L HarrisonCFOSell4,300$30.00$129,000.00View SEC Filing  
6/20/2016Thomas William BurnsCEOSell7,997$30.00$239,910.00View SEC Filing  
6/15/2016Chris M CalcaterraInsiderSell45,464$28.46$1,293,905.44View SEC Filing  
6/6/2016Thomas William BurnsCEOSell24,578$25.16$618,382.48View SEC Filing  
6/3/2016Thomas William BurnsCEOSell422$25.00$10,550.00View SEC Filing  
6/1/2016Thomas William BurnsCEOSell25,000$23.90$597,500.00View SEC Filing  
5/25/2016Thomas William BurnsCEOSell300$25.00$7,500.00View SEC Filing  
5/4/2016Chris M CalcaterraInsiderSell74,536$24.40$1,818,678.40View SEC Filing  
5/4/2016Richard L HarrisonCFOSell30,000$24.59$737,700.00View SEC Filing  
5/4/2016Thomas William BurnsCEOSell36,700$24.67$905,389.00View SEC Filing  
3/4/2016Aimee S WeisnerDirectorBuy2,500$16.03$40,075.00View SEC Filing  
2/25/2016Montreux Equity Partners Iv LpMajor ShareholderSell70,000$16.16$1,131,200.00View SEC Filing  
12/31/2015Richard L HarrisonCFOBuy1,388$15.30$21,236.40View SEC Filing  
11/12/2015Aimee S WeisnerDirectorBuy2,500$21.83$54,575.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Glaukos Corporation (NYSE:GKOS)
News IconGlaukos Corp GKOS Medical Equipment Deals and Alliances Profile [Updated: 24012017] Prices from USD $250 (NYSE:GKOS) - March 1 at 12:15 PM logoGlaukos Corporation (GKOS) Featured in Eight Presentations at AGS Meeting (NYSE:GKOS) - March 1 at 12:15 PM logoQ4 2016 Glaukos Corp Earnings Release - After Market Close (NYSE:GKOS) - March 1 at 12:15 PM logoAmedisys (AMED) Earnings Top Q4 Estimates, Revenues Lag (NYSE:GKOS) - March 1 at 12:15 PM logoGlaukos Technologies Featured in Eight Presentations at 2017 American Glaucoma Society Meeting (NYSE:GKOS) - February 28 at 5:37 PM logoGlaukos Announces Participation in 29th Annual ROTH Conference (NYSE:GKOS) - February 27 at 7:07 PM logoWill Mylan, Glaukos, Supernus Live Up To Q4 Growth Views Next Week? (NYSE:GKOS) - February 24 at 6:42 PM logoPreeminent Ophthalmologist, L. Jay Katz Joins Glaukos Corporation as Chief Medical Officer (NYSE:GKOS) - February 22 at 12:23 PM logoThese L.A.-area companies are trading at all-time highs as stocks surge in 'Trump rally' (NYSE:GKOS) - February 18 at 4:59 PM
News IconGlaukos Corp GKOS Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NYSE:GKOS) - February 18 at 12:26 PM logoMedtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT (NYSE:GKOS) - February 17 at 8:50 AM logoGNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y (NYSE:GKOS) - February 17 at 8:50 AM logoDaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4 (NYSE:GKOS) - February 17 at 8:50 AM
News IconGlaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA ® (NYSE:GKOS) - February 16 at 10:25 PM logoGlaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA® (NYSE:GKOS) - February 16 at 5:23 PM logoOmnicell Partners with DCH Health for Sterile Compounding (NYSE:GKOS) - February 14 at 6:36 PM logoPenn Mutual Life Insurance Co Buys , BlackRock Resources of Beneficial Interest, New ... (NYSE:GKOS) - February 10 at 6:03 PM logoWill Glaukos (GKOS) Continue to Surge Higher? (NYSE:GKOS) - February 10 at 4:10 AM logoGLAUKOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State (NYSE:GKOS) - February 8 at 6:00 PM logoGlaukos Corporation to Release Fourth Quarter and Full Year 2016 Financial Results after Market Close on March 1 (NYSE:GKOS) - February 8 at 6:00 PM logoGlaukos Corporation (NYSE:GKOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NYSE:GKOS) - February 7 at 6:41 PM logoGlaukos Corporation (GKOS) Names Joseph Gilliam as CFO - (NYSE:GKOS) - February 7 at 6:41 PM logo7:00 am Glaukos announces Joseph Gilliam will replace retiring CFO Richard Harrison in May 2017 (NYSE:GKOS) - February 6 at 5:30 PM logoForm 8-K GLAUKOS Corp For: Feb 06 (NYSE:GKOS) - February 6 at 11:09 AM logoJoseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate Development (NYSE:GKOS) - February 6 at 11:09 AM logoSurModics (SRDX) Beats Earnings & Revenue Estimates in Q1 (NYSE:GKOS) - February 6 at 11:09 AM logoQIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4 (NYSE:GKOS) - February 3 at 5:51 PM logoGlaukos Corporation Promotes Chris M. Calcaterra to Chief Operating Officer (NYSE:GKOS) - February 1 at 6:06 PM logo4:32 pm Glaukos appoints its Chief Commerical Officer Chris M. Calcaterra as COO, effective immediately (NYSE:GKOS) - February 1 at 6:06 PM
News IconGlaukos Corp (GKOS)'s Trend Up, Especially After Forming a Double Top Pattern - The Randolph Guide (NYSE:GKOS) - January 30 at 11:09 PM
News IconUpdate on Valuation Formula's For Glaukos Corporation (NYSE:GKOS) - The Tribune (NYSE:GKOS) - January 29 at 5:28 PM
News IconTrading Indicator Check on Glaukos Corp. (GKOS) - Springdale Times (NYSE:GKOS) - January 29 at 5:28 PM
News IconInvestor Watch: Checking in on Shares of Glaukos Corporation ... - The Tribune (NYSE:GKOS) - January 27 at 7:21 PM
News IconHamilton Lane Advisors Cuts Position in Glaukos Corp (GKOS) by $3014707 - Highland Mirror (NYSE:GKOS) - January 27 at 7:21 PM
News IconAnalysts Take: Glaukos Corp (NYSE:GKOS) Projected Earnings & Price Targets - Aiken Advocate (NYSE:GKOS) - January 26 at 6:52 PM
News IconEarnings in Full Force, Analysts Take Aim at Glaukos Corp (NYSE:GKOS) - Wall Street Beacon (NYSE:GKOS) - January 25 at 4:43 PM
News IconHershey Trust Co adds Glaukos Corp (GKOS) by $313500 - Highland Mirror (NYSE:GKOS) - January 25 at 4:43 PM
News IconStock Tracker: Trend Analysis on Glaukos Corp. (GKOS) - Rives Journal (NYSE:GKOS) - January 22 at 5:21 PM
News IconTechnical Indicator Review on Shares of Glaukos Corp. (GKOS) - Sherwood Daily (NYSE:GKOS) - January 21 at 5:21 PM
News IconInstitutions Taking Notice Of This Stock in Q4: Glaukos Corporation (NYSE:GKOS) - Wall Street Beacon (NYSE:GKOS) - January 20 at 6:46 PM logoCan Glaukos (GKOS) Stock Continue to Grow Earnings? (NYSE:GKOS) - January 19 at 7:09 PM logoInvesting in Earlier Stage Small Cap Growth Companies - Baron Discovery Fund (NYSE:GKOS) - January 18 at 5:52 PM logoBaron Funds Comments on Glaukos Corporation (NYSE:GKOS) - January 18 at 5:52 PM logoMedidata Solutions Clinical Cloud Gets Picked by Celgene (NYSE:GKOS) - January 17 at 8:40 AM logo5 Stocks with Recent Price Strength to Boost Your Returns (NYSE:GKOS) - January 17 at 8:40 AM logoAkers Biosciences (AKER) Closes Offering of 1.7M Shares (NYSE:GKOS) - January 16 at 9:25 AM logo4 Profitable Stocks with Amazingly High Returns (NYSE:GKOS) - January 16 at 9:25 AM
News IconFirst Week of February 17th Options Trading For Glaukos (GKOS) (NYSE:GKOS) - January 13 at 6:24 PM logoOn second thought, maybe the ‘Trump rally’ has months left to run — and here’s why (NYSE:GKOS) - January 13 at 6:24 PM logoCan the Rally in Glaukos (GKOS) Shares Continue? - - Nasdaq (NYSE:GKOS) - January 12 at 3:18 PM


What is Glaukos Corporation's stock symbol?

Glaukos Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Where is Glaukos Corporation's stock going? Where will Glaukos Corporation's stock price be in 2017?

7 brokerages have issued twelve-month price targets for Glaukos Corporation's stock. Their forecasts range from $28.00 to $55.00. On average, they anticipate Glaukos Corporation's share price to reach $44.17 in the next year.

When will Glaukos Corporation announce their earnings?

Glaukos Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

What are analysts saying about Glaukos Corporation stock?

Here are some recent quotes from research analysts about Glaukos Corporation stock:

  • Stifel Nicolaus analysts commented, "Glaukos' stock has considerably outperformed the market YTD (+29% relative to the S&P). We attribute the strong performance to ongoing positive investor sentiment as well as a better understanding of the pricing power that the company possesses in 2017 due to the favorable Ambulatory Surgical Center (ASC) reimbursement decision that took hold at the beginning of the year. While Glaukos does not plan to provide ASP details, our late January diligence among a small number of iStent physicians unveiled that Glaukos is in the midst of implementing a significant price increase (~40%) among iStent cases performed at the ASC. A price increase of this magnitude implies upside to the Street's current 2017 revenue estimate of $147.5MM (we are at $151.4MME), and our January report laid out a case where 2017 revenue could total $180MM+. As investors have better understood the power of price over the past few weeks, we believe the bar has been raised into the company's 2017 guidance, which will be provided on Wednesday (AMC). In this report, we take a near-term look at what different 2017 revenue guidance levels imply for 2017 iStent volumes based on our ASP diligence. We also take a longer-term look at Glaukos' future earnings power, which we view as significant, and believe will become more evident in 2H17 / 1H18. Simply put, we can see 2019 adjusted EBITDA per share (which we use as a proxy for cash EPS) of $2.23 to $3.33, which does not include future pipeline products such as iDose, or the significant market opportunity associated with the stand-alone Glaucoma market." (2/28/2017)
  • According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (1/10/2017)

Who owns Glaukos Corporation stock?

Glaukos Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (6.50%), William Blair Investment Management LLC (5.84%), Interwest Venture Management Co. (3.04%), Federated Investors Inc. PA (2.87%), Janus Capital Management LLC (2.79%) and Renaissance Technologies LLC (2.53%). Company insiders that own Glaukos Corporation stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link.

Who sold Glaukos Corporation stock? Who is selling Glaukos Corporation stock?

Glaukos Corporation's stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Two Sigma Investments LP, Deerfield Management Co., Employees Retirement System of Texas and Federated Investors Inc. PA. Company insiders that have sold Glaukos Corporation stock in the last year include Chris M Calcaterra, Jonathan Silverstein, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link.

Who bought Glaukos Corporation stock? Who is buying Glaukos Corporation stock?

Glaukos Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., William Blair Investment Management LLC, Janus Capital Management LLC, Artisan Partners Limited Partnership, Russell Investments Group Ltd., Advisory Research Inc., Renaissance Technologies LLC and Broadfin Capital LLC. Company insiders that have bought Glaukos Corporation stock in the last two years include Aimee S Weisner and Richard L Harrison.

How do I buy Glaukos Corporation stock?

Shares of Glaukos Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Glaukos Corporation stock cost?

One share of Glaukos Corporation stock can currently be purchased for approximately $45.50.

Glaukos Corporation (NYSE:GKOS) Chart for Wednesday, March, 1, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Earnings History Chart

Earnings by Quarter for Glaukos Corporation (NYSE:GKOS)

Dividend History Chart

Dividend Payments by Quarter for Glaukos Corporation (NYSE:GKOS)

Last Updated on 3/1/2017 by Staff